Bosutinib approved for chronic myelogenous leukemia The FDA has approved bosutinib (Bosulif, Pfizer) for patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML, who are ...

—In Europe, patients with Philadelphia chromosome-positive CML generally have better rates of survival than similar patients in the U.S. These investigators at MD Anderson Cancer Center tried to ...

Chronic myeloid leukemia (CML) is a type of blood cancer that arises from malignant changes in blood-forming cells of the bone marrow. It mainly occurs in older individuals and represents about 20% of ...

Tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment, offering more effective and better-tolerated options than previous therapies. Second- and third-generation TKIs address resistance ...

Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.

When you talk to your doctor about treatment for chronic myelogenous leukemia (CML), you may hear him say that your goal is to get into remission. If you're like most folks, you've got a general idea ...

VAD (vincristine, doxorubicin and high-dose dexamethasone) administered as intravenous bolus (IVB) injection as first-line treatment in multiple myeloma (MM) Background: Imatinib mesylate is a novel ...

Please provide your email address to receive an email when new articles are posted on . In this video, Christine McMahon, MD, discusses the results of the phase 3 ASC4FIRST study, pertaining to ...

Researchers recently calculated the estimated savings over a 30-year period with regard to CML patients who attempt to get off their TKI therapy. In what they referred to as a 'conservative' estimate, ...

Gleevec, a cancer drug first approved for sale in 2001, has dramatically changed the lives of people with chronic myeloid leukemia. This form of cancer was once regarded as very difficult to combat, ...